A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population

NCT07201831 | Completed

• 2 other identifiers: DAS-8185U1111-1308-2796
• Study Type: observational
• Target: 1,330
• Locations: 5 countries
• Sites: 5

Brief Summary

The purpose of this study is to collect information for scientific research and to better understand awareness and to understand overall risk awareness, diagnoses and treatment related to liver related diseases. The study aims to collect valid responses through online questionnaires from the participants. This study is a survey-based study without collection of laboratory data. It will take the participant 25 minutes to complete the survey. The study is not related to any specific treatment options or pharmaceutical product.

Conditions

Metabolic Dysfunction-associated Steatohepatitis (MASH)

Outcome Measures

Primary Outcomes (2)

• Description of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors

  Healthcare Provider (HCP) Quantitative Segment 7-point Likert scale 1 indicates very strongly disagree and 7 indicates very strongly agree

  At the time of survey (Day 1)

• Description of awareness, understanding, and perception of MASLD/MASH, comorbidities, and risk factors

  Patient Quantitative Segment 7-point Likert scale 1 indicates very strongly disagree and 7 indicates very strongly agree

  At the time of survey (Day 1)

Study Arms (2)

HCP Group

This group includes Health Care Practitioners (HCPs) who self-report to being at least somewhat familiar with Metabolic dysfunction-associated steatohepatitis (MASH)

Other: No treatment given

Patient Groups

This group includes patients diagnosed with Metabolic dysfunction-associated steatohepatitis (MASH), diagnosed with Metabolic Associated Steatotic Liver Disease (MASLD), or at risk for development/diagnosis of MASH

Other: No treatment given

Interventions

No treatment given OTHER

No treatment given

HCP Group; Patient Groups

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population includes two population segments. The first segment is made up of Health Care Practitioners (HCPs) who self-report to being at least somewhat familiar with Metabolic dysfunction-associated steatohepatitis (MASH). The second segment consists of three subsegments defined as people who have been diagnosed with MASH, or people who have been diagnosed with Metabolic Associated Steatotic Liver Disease (MASLD), or people who have been identified as being at risk for developing MASH

You may qualify if:

• Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• Male or female, age above or equal to 18 years at the time of signing informed consent.
• Licensed to practice medicine in one of the countries of interest: United States, Canada, France, Germany, Japan
• Must be a practicing endocrinologist, hepatologist, cardiologist, obesity specialist, primary care physician, radiologist, nurse practitioner or physician assistant (NP/PA US only)
• Must be at least "somewhat familiar" (as opposed to "not at all familiar) with Metabolic dysfunction-associated steatohepatitis (MASH) (do not need to be currently treating people with MASH) 6. Must have at least 2 years in practice 7. Must spend at least 50 percentage of their time in patient care
• Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• Male or female, age above or equal to 18 years at the time of signing informed consent.
• Diagnosis of MASH or Metabolic Associated Steatotic Liver Disease (MASLD) within past 24 months
• Live in one of the countries of interest: United States, Canada, France, Germany, Japan
• Have at least one comorbid condition: obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease
• Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• Male or female, age above or equal to 18 years at the time of signing informed consent.
• Live in one of the countries of interest: United States, Canada, France, Germany, Japan
• Must have one or more risk factors associated with MASH \[obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease\], be diagnosed with steatosis (incidental finding) or have a blood test that shows raised liver enzymes.

You may not qualify if:

• Previous participation in this study. Participation is defined as having given informed consent in this study
• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (5)

Novo Nordisk Investigational Site

Plainsboro, New Jersey, 08536, United States

Location

Novo Nordisk Investigational Site

Mississauga, Canada

Location

Novo Nordisk Investigational Site

Puteaux, France

Location

Novo Nordisk Investigational Site

Mainz, Germany

Location

Novo Nordisk Investigational Site

Tokyo, Japan

Location

Study Officials

• Clinical Transparency dept. 2834

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 18, 2025
• First Posted: October 1, 2025
• Study Start: October 2, 2025
• Primary Completion: January 17, 2026
• Study Completion: January 17, 2026
• Last Updated: March 12, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share

Locations

FR (1); DE (1); JP (1); US (1); CA (1)